Stocks · News reference
Rapport Therapeutics posts positive Phase 2 trial results for RAP-219 in acute bipolar mania, setting up Phase 3 studies in 2027.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Rapport Therapeutics announced the pricing of its previously proposed public offerings, totaling approximately $175 million in common stock and $150 million in convertible senior notes.
Rapport Therapeutics has commenced separate underwritten public offerings of $200 million in common stock and $150 million in convertible senior notes due 2032.
Goldman Sachs analyst Salveen Richter maintained a 'Buy' rating on Rapport Therapeutics and increased the price target from $62 to $68.